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A randomized trial and novel 
SPR technique identifies altered 
lipoprotein-LDL receptor binding as 
a mechanism underlying elevated 
LDL-cholesterol in APOE4s
M. V. Calabuig-Navarro1,2,*, K. G. Jackson1,2,*, C. F. Kemp3, D. S. Leake2, C. M. Walden4, 
J. A. Lovegrove1,2 & A. M. Minihane1,†
At a population level APOE4 carriers (~25% Caucasians) are at higher risk of cardiovascular diseases. The 
penetrance of genotype is however variable and influenced by dietary fat composition, with the APOE4 
allele associated with greater LDL-cholesterol elevation in response to saturated fatty acids (SFA). The 
etiology of this greater responsiveness is unknown. Here a novel surface plasmon resonance technique 
(SPR) is developed and used, along with hepatocyte (with the liver being the main organ modulating 
lipoprotein metabolism and plasma lipid levels) uptake studies to establish the impact of dietary fatty 
acid composition on, lipoprotein-LDL receptor (LDLR) binding, and hepatocyte uptake, according 
to APOE genotype status. In men prospectively recruited according to APOE genotype (APOE3/3 
common genotype, or APOE3/E4), triglyceride-rich lipoproteins (TRLs) were isolated at fasting and 
4–6 h following test meals rich in SFA, unsaturated fat and SFA with fish oil. In APOE4s a greater LDLR 
binding affinity of postprandial TRL after SFA, and lower LDL binding and hepatocyte internalization, 
provide mechanisms for the greater LDL-cholesterol raising effect. The SPR technique developed may 
be used for the future study of the impact of genotype, and physiological and behavioral variables on 
lipoprotein metabolism. Trial registration number NCT01522482.
Although recent meta-analyses suggest no overall association between saturated fat (SFA) intake and cardiovas-
cular disease (CVD) incidence or mortality1, the LDL-cholesterol lowering effects of the replacement of dietary 
SFA with unsaturated fatty acids is well established2–4. Individuals with an APOE4 genotype (~25% Caucasians) 
are particularly sensitive5,6 with this responsiveness providing APOE4 carriers with a tractable means of reducing 
the penetrance of this ‘at-risk’ genotype. A 20–30% reduction in population SFA intake in Western Countries 
since the 1970s7 may go a long way towards explaining the apparent attenuation in reported relative risk of coro-
nary heart disease associated with the APOE4 allele in recent decades8–11. However although repeatedly observed, 
an understanding of the mechanistic basis for the greater sensitivity to dietary fat composition in APOE4 carriers 
is lacking. Such biological plausibility would provide justification for the targeting of APOE4 individuals as a large 
population subgroup who would particularly benefit from reduced SFA intakes.
ApoE, found in the circulation on the surface of high density lipoproteins (HDL) and triglyceride-rich lipo-
proteins (TRL, chylomicrons (CM), VLDL and their remnants) is involved in lipoprotein production, and hepatic 
clearance from the circulation by acting as a high affinity ligand for the LDL receptor (LDLR) family5,12. Unlike 
the cholesterol-rich VLDL2 and LDL which mainly use apoB-100, apoE acts as the primary ligand for the uptake 
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of triglyceride-rich VLDL113. A competition study performed in vitro showed that the uptake of LDL by HepG2 
(liver) cells is reduced in the presence of apoE-containing TRL predominately in the VLDL1 density range14. A 
greater enrichment of the TRL particles with apoE after a SFA-rich meal reduced the HepG2 LDL uptake rela-
tive to TRL isolated after meals containing unsaturated fatty acids14. A more recent human ex vivo investigation 
has shown that smaller TRL (predominately VLDL2) isolated from APOE4 carriers reduced the uptake of LDL 
compared with the wild-type APOE3/E3 group15. Therefore a greater competition between TRL isolated from 
E4 carriers with LDL for uptake by the LDLR may provide an explanation for the higher fasting LDL-cholesterol 
and in particular against a high SFA background diet. However, such ‘competition’ studies based on the uptake 
of 125I-labelled LDL do not provide a holistic overview of lipoprotein metabolism focusing only on the fate of the 
LDL particles, with no information about the binding properties of TRL with the LDLR and subsequent hepato-
cyte internalization.
Surface plasmon resonance (SPR), is a sensor based technology that allows the interaction of biological mol-
ecules to be determined in real-time16,17. The technique has previously been used to investigate the binding of 
purified apoE and apoB to lipoprotein particles18 or to specific receptors12,19–21. However, little is known about the 
kinetics of the more physiologically relevant scenario of the binding of intact lipoprotein particles (containing 
apoB and apoE) to the LDLR. Thus the initial aim of this ex vivo study series was to develop a SPR technique for 
use in the study of lipoprotein metabolism and specifically the binding of lipoproteins to the LDLR. This was then 
applied, together with uptake studies in a HepG2 cell model to investigate the effects of APOE genotype and meal 
fat composition on the ex vivo binding of TRL and LDL to the LDLR and hepatic lipoprotein uptake. In addition 
to SFA and PUFA we investigated the impact of the fish derived n-3 fatty acid docosahexaenoic acid (DHA) on 
lipoprotein binding. The LDL-cholesterol raising effect of high dose DHA has been repeatedly described22 with 
inconsistent evidence indicating this may be partly APOE genotype dependent15,23,24.
Materials and Methods
Subjects and study design. The subject group, test meal composition and postprandial study day are 
described in detail in a previous publication25. Briefly n = 31 healthy men (mean ± SD, age 48 ± 16 y, BMI 
25.7 ± 2.7 kg/m2) were prospectively recruited according to APOE genotype in Reading, UK, from the University 
of Reading and surrounding area between January 2009 and April 2009, with the intervention completed by Dec 
2009. Participants underwent a single blind randomized cross-over trial, consuming on 3 separate occasions a 
mixed meal containing 53 g of fat, of which 50 g was provided in the form of a test oil rich in either SFA (29 g 
palm oil and 21 g cocoa butter), unsaturated fatty acids (UNSAT, 7.2 g rapeseed oil, 16.2 g soybean oil and 26.6 g 
olive oil) or SFA with fish oils (SFA-FO, 22 g palm oil, 18 g cocoa butter and 10 g fish oil, DHA:EPA 7.3:1), in 
random order. The order of intervention was decided by the trial statistician based on simple randomization and 
a web-based random letter sequence generator. APOE3/E3 (n = 10) and APOE3/E4 (n = 11) completed all three 
intervention arms.
Blood samples were collected at fasting and 180, 240, 300, 360 and 480 min after the test meals. The study and 
all experimental protocols were approved by the University of Reading Research Ethics Committee. All methods 
were conducted according to the guidelines in the Declaration of Helsinki. All participants gave their written 
informed consent before commencing the study. This trial was registered at clinicaltrials.gov as NCT01522482 
(26th January 2012).
Preparation of lipoprotein fractions for SPR analysis and HepG2 cell studies. Blood for LDL 
isolation was obtained from an independent group of healthy APOE3/E3 and APOE3/E4 male subjects after an 
overnight fast. LDL (density 1.019–1.063 g/ml) was isolated as described previously26. A portion of the LDL frac-
tion from each genotype group was radiolabeled using iodogen27.
TRL fractions, Svedberg flotation rate (Sf) 60–400 (contains predominately VLDL1 particles, and so this frac-
tion will be referred to in the remainder of the paper as VLDL1-rich) and Sf 20–60 (VLDL2-rich) were isolated 
from both fasting (0 min) and postprandial plasma28. The time point chosen for the postprandial sample for 
in vitro studies represented the individual’s peak VLDL1-rich fraction apoB and apoE concentration (usually 
between 240–360 min) observed after each meal in our human study25. In order to ensure a sufficient yield of 
apoB containing lipoproteins in the VLDL1-rich and VLDL2-rich TRL fractions, the samples were pooled from 
two subjects before desalting through PD-10 desalting columns (Amersham Biosciences, Chalfont St. Giles, UK) 
and further concentrated using Vivaspin concentrators (Sartorius Ltd, Epsom, UK). Since different salt solutions 
were used for the isolation of the TRL fractions and LDL, the VLDL1-rich and VLDL2-rich fractions were further 
dialyzed against 0.02 M phosphate buffer containing 100 μ M EDTA for 24 h at 4 °C to minimize the effects of the 
salt solution on the binding signal during the SPR analysis. Apos B and E were measured using an ILAB600 clin-
ical chemistry analyzer (Instrumentation Laboratory, Warrington, UK) by turbidimetric immunoassay (Kamiya 
Biomedical, Seattle, USA).
Surface plasmon resonance (SPR). The binding affinity of the lipoproteins to the LDLR receptor, was 
investigated with a BIAcore 3000 SPR instrument (GE Healthcare, Little Chalfont, UK) using a CM5 sensor chip 
(GE Healthcare). This technique measures changes in the refractive index near the sensor surface29, that is pro-
portional to the mass of the analyte when it binds to the ligand (generally a receptor) immobilized on the chip 
surface. This change in refractive index is monitored in real time and is displayed as a sensorgram (see Fig. 1)30–32.
Purified LDLR ectodomain (R & D Systems, Abingdon, UK) diluted with acetate buffer (pH 5.0; GE 
Healthcare) to a final concentration of 10 μ g/ml, was immobilized onto the surface of a CM5 sensor chip with a 
target of 1000 resonance units (RU) by amine coupling in accordance with the manufacturer’s instructions (GE 
Healthcare). A flow cell on the chip without the addition of LDLR was used as a control. The final step involved 
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deactivation of the excess reactive groups on the surface of the CM5 sensor chip using 1 M ethanolamine-HCl 
(pH 8.5) to prevent non-specific binding of the lipoproteins to the chip surface.
The concentrated lipoprotein fractions (VLDL1-rich, VLDL2-rich and LDL) were diluted to a final concen-
tration of 5 nM apoB in filtered running buffer (HBS-N 1X (pH 7.4, 0.01 M HEPES, 0.15 M sodium chloride, GE 
Healthcare)) containing 0.5% BSA (w/v) and 1 mM calcium chloride. The diluted samples were filtered through 
0.22 μ m filters (Millipore, USA) before injection to remove aggregated proteins that could interfere with LDLR 
binding. To ensure that binding of the lipoprotein fractions to the LDLR was not influenced by mass transfer 
effects (i.e. size of the lipoprotein particles) all binding experiments were performed at 25 °C using a flow rate 
of 30 μ l/min for 3 min. Following dissociation of the lipoprotein particles from the LDLR, the sensor chip sur-
face was regenerated with 7.5 mM sodium hydroxide in 100 mM EGTA. Individual lipoprotein samples (LDL, 
VLDL1-rich or VLDL2-rich TRL) were injected in duplicate and two blanks (running buffer) were injected every 
10 samples to decrease the loss of activity of the chip surface. A control VLDL1-rich sample was injected at the 
beginning and at the end of each experiment to assess for both inter- and intra-assay variation and to ensure the 
functionalized surface (LDLR) retained sufficient binding activity throughout the analysis period.
The sensorgram data were analyzed with BIA evaluation 4.1 software (GE Healthcare). Sensorgram curves 
are displayed as RU versus t, where RU is the SPR signal response and t is time per second. For a CM5 chip, a 
response of 1 RU is equivalent to a change in surface concentration of LDLR of approximately 1 pg/mm2. The sen-
sorgram data corresponding to the injection and post injection phases were used to perform the kinetic analysis 
to determine the best model fit for the binding of the lipoproteins to the LDLR. This was evaluated by calculating 
the goodness-of fit Chi-square distribution (Chi2) value, residual range and visual inspection of the fitted model.
Cell culture and 125I-labelled LDL uptake studies. HepG2 cells (European Collection of Cell Culture, 
Centre for Applied Microbiology and Research, Salisbury, UK), were grown to 80% confluence in 24 well plates 
and maintained in charcoal-stripped lipoprotein-deficient serum (First Link UK, Birmingham, UK) for the 48 h 
prior to the addition of the lipoprotein fractions (LDL and TRL) to the medium, in order to upregulate LDLR on 
the cell surface.
Total LDL uptake which is the sum of the cell surface bound (heparin-releasable binding) and internalized 
125I-LDL (cell associated radioactivity) including degradation products in the medium, was determined as 
described by Goldstein, Basu and Brown33 with a few modifications14. Briefly, 125I-labelled LDL at a final con-
centration of 10 μ g protein/ml was added to the medium of HepG2 cells alone and simultaneously with 15 μ g 
apoB/ml of VLDL1 or VLDL2-rich fractions for 5 hr at 37 °C. In all experiments, individual TRL fractions were 
incubated with 125I-labelled LDL from the same APOE genotype group. The results were expressed as a percentage 
relative to the incubation of the HepG2 cells with 125I-LDL alone.
Statistical Analysis. Data were analyzed using SPSS software version 17.0 (SPSS Inc Chicago, USA). 
Results are presented as means ± SD or SEM. Data were checked for normality using the Shapiro-Wilk test and 
log-transformed where necessary. A Student’s independent t-test was used to determine differences in the base-
line (fasting) binding properties of the lipoprotein samples to the LDLR and 125I-labelled LDL total uptake in the 
presence of fasting TRL fractions between genotype groups (E3/E3 and E3/E4). For the binding properties of the 
postprandial TRL samples to the LDLR and HepG2 cell data, a mixed factor ANOVA with repeated measures was 
used, with test meal and genotype as the ‘within’ and ‘between’ factors respectively. A Bonferroni correction was 
used for the post hoc detection of significant pair wise differences. Values of P ≤ 0.05 were given to be statistically 
significant.
Results
Development of the SPR technique to study lipoprotein metabolism. In order to study the bind-
ing affinities of different lipoprotein classes to the LDLR, LDL and TRL fractions were injected over a range of 
apoB concentrations (to normalize for particle number) to determine the concentration that resulted in the opti-
mal binding signal to the LDLR. An example of a typical sensorgram showing the binding and dissociation of the 
Figure 1. Sensorgram of the interaction between VLDL-1 rich particles (ranging from 0 to 40 nM apoB) 
and the LDL-receptor immobilized on the surface of a CM5 sensor chip. Experimental data (dotted lines) 
was fitted with the two-state binding model (solid line).
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VLDL-1 rich fraction particles over a range of apoB concentrations is given in Fig. 1. The final apoB concentration 
chosen for our subsequent SPR analysis was 5 nM; higher apoB concentrations deviated from the model (higher 
ChiChi2 values, data not shown) and lower concentrations were affected by the loss of activity of the chip surface 
after repeated regeneration conditions. For interpretation of the specificity of lipoprotein binding to the LDLR, 
the data were corrected for the bulk refractive index effect (associated with buffer washes). It was fitted using a 
two-state binding model since a lower ChiChi2 indicated that this was a better model fit compared with the 1:1 
Langmuir binding model (data not shown). In this model (summarized in Fig. 2), lipoproteins (A) bind to the 
LDLR (B) to form complex AB, followed by a conformational change to form a more stable complex AB* (Fig. 3).
The binding of LDL to the LDLR was best described by the heterogeneous ligand model, as lower ChiChi2 
values were observed compared with the two-state binding model (Chi2 = 0.412 vs 1.070, respectively). The dif-
ferences in model-fits between LDL and TRL fractions can also be observed in the shape of the curves in the 
sensorgram (Fig. 4). However, the information that this model provides did not allow the direct comparison with 
the two state model used for the TRL samples. When the ChiChi2 values were compared between both models for 
LDL, no statistical differences were observed (P = 0.24 and P = 0.19 for LDL isolated from APOE3/E3 and from 
APOE3/E4 subjects, respectively). An additional comparison of F-values (F = 3.8e-6 for the heterogeneous ligand 
model, F = 9.9e-5 for the two state model), confirmed either were acceptable models to use, so the two state model 
was chosen for the analysis of all samples, as this would give the most directly comparable results, and allow for 
the identification of differences between the two interactions.
In order to establish variability, control VLDL1 sample were included in each run, which yielded intra- and 
inter-assay % CV of 5.3% (n = 8) and 9.7% (n = 5) for KA values.
APOE genotype affects the binding of fasting lipoproteins to the LDLR. Overall the global affinity 
(KA) of the different lipoprotein fractions for binding to the LDLR in the fasting state are in the following order 
Figure 2. Binding of lipoproteins to the LDL-receptor. Lipoproteins (A) bind to the LDLR (B) to form 
complex AB, followed by a conformational change to form a more stable complex AB*. The association rate 
constants are ka1 and ka2 and the dissociation rate constants are kd1 and kd2. The equilibrium constant for 
each binding step are K1 =   ka1/kd1 and K2 = ka2/kd2. The overall equilibrium binding constants are therefore 
KA = K1 (1 + K2) and KD = 1/KA.
Figure 3. Overview of the sensorgrams for the two state conformational change reaction 
(A + B ↔ AB ↔ AB*). The output response (solid line) is the sum of the individual responses for the fast 
process to form AB and the conformational change to form the more stable complex AB*. Reprinted from 
Morton et al. (1985) with permission from the author29.
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VLDL1-rich TRL > VLDL2-rich TRL > LDL, which reflects differences in the formation of the stable AB* com-
plex (ka2) which is faster with TRL and dissociates at a slower rate (kd2) relative to LDL.
APOE genotype impacted on the equilibrium constant with a lower K1 (P = 0.005) and K2 (P = 0.019) evident 
for LDL isolated from APOE3/E4 compared with the APOE3/E3 subjects (Table 1). This was reflected in the KA 
(0.5 × 109 M−1 vs. 0.7 × 109 M−1, respectively) (P = 0.019) indicating that LDL isolated from APOE3/E4 subjects 
had a lower binding affinity to the LDLR relative to the APOE3/E3 genotype.
Relative to the APOE3/E3 group, the dissociation rate constant (kd2) was lower (P = 0.013) and overall K2 
was higher (P = 0.032) for the second step of the binding of fasting APOE3/E4 VLDL1-rich particles to the LDLR. 
This indicates that once the AB* complex is formed, it is more stable and dissociates at a slower rate after binding 
of fasting VLDL1-rich samples from E3/E4 subjects to the LDLR. There were no significant genotype effects 
observed for the binding of the fasting VLDL2-rich fraction (Table 1), nor on the apoE content of either fasting 
TRL fraction estimated using the apoE/apoB ratio.
ApoE content of the postprandial TRL particles. A significant meal effect was observed for the apoE/
apoB ratio in the postprandial VLDL1- rich fraction (P = 0.023), with 2.9 ± 0.4, 2.9 ± 0.7 and 1.7 ± 0.5 apoE 
molecules per particle following the SFA, SFA-FO and UNSAT meal respectively. A tendency for an effect of meal 
fatty acid intake on the apoE/apoB ratio in the VLDL2-rich fraction was also evident with 2.1 ± 0.7, 1.4 ± 0.4 and 
1.4 ± 0.3 apoE molecule per particle following the SFA, SFA-FO and UNSAT meals respectively (P = 0.100). No 
impact of genotype on the TRL apoE/apoB ratios were evident.
APOE genotype and the binding of postprandial TRL fractions to the LDLR. There were no sig-
nificant genotype or meal*genotype interactions observed for the binding of postprandial TRL fractions to the 
LDLR. Therefore, data for the two genotype groups were combined to determine the overall effect of the SFA, 
SFA-FO and UNSAT meals on the binding affinities of the postprandial TRL (Table 2). An almost 2-fold increase 
in KA of the VLDL1-rich fraction to the LDLR was observed following the SFA relative to the SFA-FO or UNSAT 
Figure 4. Effects of test meal composition on the binding of postprandial VLDL-1 rich TRL compared with 
fasting LDL particles to immobilized LDLR on a CM5 chip. The figure represents single pooled samples (from 
two study participants) post SFA, UNSAT and SFA-DHA meal consumption, run in duplicate. The lipoprotein 
fractions were normalized for lipoprotein particle number using apoB concentration. Abbreviations: SFA, 




LDL VLDL1-rich TRL VLDL2-rich TRL
APOE3/E3 APOE3/E4 P genotype APOE3/E3 APOE3/E4 P genotype APOE3/E3 APOE3/E4 P genotype
ka1 × 105 (M−1s−1) 21.5 ± 1.0 14.5 ± 3.9 0.77 11.3 ± 0.4 9.3 ± 0.5 0.011 10.6 ± 0.4 10.3 ± 0.4 0.71
kd1 × 10−3 (s−1) 11.7 ± 0.2 12.7 ± 0.3 0.042 6.2 ± 0.8 5.2 ± 0.5 0.28 6.0 ± 0.3 7.3 ± 1.1 0.38
K1 × 108 (M−1) 1.8 ± 0.1 1.4 ± 0.2 0.005 2.0 ± 0.3 1.9 ± 0.2 0.37 1.8 ± 0.1 1.7 ± 0.4 0.85
ka2 × 10−2 (s−1) 0.7 ± 0.0 0.6 ± 0.0 0.22 1.5 ± 0.1 1.7 ± 0.1 0.12 1.2 ± 0.1 1.2 ± 0.1 0.92
kd2 × 10−4 (s−1) 25.4 ± 0.6 28.7 ± 1.0 0.031 11.2 ± 0.2 9.7 ± 0.4 0.013 10.6 ± 0.1 11.3 ± 0.5 0.28
K2 2.6 ± 0.1 1.7 ± 0.3 0.019 13.2 ± 0.8 17.3 ± 1.4 0.032 11.6 ± 0.8 11.1 ± 1.2 0.76
KA × 109 (M−1) 0.7 ± 0.0 0.5 ± 0.0 0.019 2.7 ± 0.4 3.3 ± 0.3 0.21 2.2 ± 0.2 1.9 ± 0.4 0.49
Table 1.  APOE genotype influences the binding properties of fasting LDL, VLDL1-rich, and VLDL2-rich 
particles to the LDLR. Values are listed as mean ± SEM for n = 5 independent SPR experiments performed 
using LDL, Sf 60–400 and Sf 20–60 isolated from the APOE3/E3 and APOE3/E4 individuals in the fasted state. 
Association rate constants are expressed as ka1 and ka2; dissociation rate constants kd1 and kd2. Affinity 
constants are expressed as K1, K2 and KA for the two-state reaction model A + B ↔ AB ↔ AB*. Differences 
between genotype groups were compared using the Student’s independent t-test (P ≤ 0.05).
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meals (P ≤ 0.001; Fig. 3 and Table 2), which reflects a higher ka1 (P = 0.004), K1 (P = 0.007), and lower kd1 
(P = 0.047).
Less marked effects of meal composition were observed for the VLDL2-rich fraction. Meal fat composition 
was shown to influence the rate of association of the AB* complex (ka2) (P = 0.011) (Table 2), indicating a higher 
rate of conversion of AB into the stable AB* complex with particles isolated following the SFA than UNSAT meal. 
Although the impact did not reach significance (P = 0.09), as observed in the VLDL1-rich fraction, the KA for the 
VLDL2-rich fraction was in the order SFA > SFA-FO > UNSAT.
Genotype and meal fat composition influence 125I-labelled LDL uptake on co-incubation with 
TRL. The concentration of the TRL samples used in the competition studies were normalized for the apoB con-
tent (15 μ g apoB/ml) to control for particle number. In the fasting state a significant genotype effect was observed 
for the percentage of 125I-LDL bound to the surface of the HepG2 cells (heparin releasable binding), with a lower 
percentage binding in the presence of the VLDL1-rich (P = 0.001) and VLDL2-rich (P = 0.038) fractions isolated 
from APOE3/E4 than APOE3/E3 individuals (Table 3). Genotype effects were not observed for the percentage 
cell associated radioactivity (internalized), degradation products (released into the medium) or total uptake of 
125I-LDL following co-incubation with the fasting TRL fractions.
In the postprandial state, a significant meal*genotype interaction (P = 0.046) was observed for the per-
centage heparin releasable binding of 125I-LDL in the presence of postprandial VLDL1-rich particles, with a 
non-significant tendency for a similar relationship for the total uptake (P = 0.07). Within the APOE4 carrier 
group, this reflected a 38–40% and 15–17% lower percentage of heparin releasable binding and total uptake of 
125I-LDL in the presence of VLDL1-rich particles after the SFA-rich meal compared with the UNSAT and SFA-FO 
meals. Differences were not evident between meals in the APOE3/E3 group (Table 3).
In the genotype groups combined, there was a significant meal effect for the cell associated radioactivity and 
total uptake of 125I-LDL in the presence of postprandial VLDL1-rich particles (P = 0.05). A lower percentage total 
uptake was observed with TRL isolated following the SFA meal (69%) compared with the SFA-FO (79%) and 
UNSAT (75%) meals (P = 0.038).
For the VLDL2-rich fraction, in APOE3/E4, the percentage cell associated 125I-LDL was lower in the presence 
of particles isolated following the SFA (57%) and UNSAT (71%) meals relative to the SFA-FO (89%) (meal * geno-
type interaction, P = 0.047) which was reflected in a trend (P = 0.07) towards lower total 125I-labelled LDL uptake 
in the presence of SFA-enriched particles.
Discussion
The replacement of saturated with unsaturated fats is an effective and widely recommended population dietary 
strategy to lower plasma total- and LDL-cholesterol. APOE4 carrier status is associated with an ~1.5 fold higher 
CVD risk in some but not all studies (for meta-analysis see refs 8 and 10), moderately raised LDL-cholesterol8, 
and a greater responsiveness to dietary fatty acid composition5,6,34,35. However the mechanistic basis for these 
associations is largely unknown, with an unsubstantiated suggestion that an APOE4 genotype may be associated 
Fraction SFA SFA-FO UNSAT P meal
VLDL1-rich
ka1 × 105 (M−1s−1) 9.4 ± 0.5a 8.4 ± 0.5b 7.9 ± 0.6b 0.004
kd1 × 10−3 (s−1) 3.8 ± 0.7a 4.1 ± 0.6a,b 4.8 ± 0.1b 0.047
K1 × 108 (M−1) 3.2 ± 0.6a 2.4 ± 0.6b 1.5 ± 0.1b 0.007
ka2 × 10−2 (s−1) 1.6 ± 0.2 1.4 ± 0.1 1.5 ± 0.1 0.67
kd2 × 10−4 (s−1) 7.9 ± 0.7 9.2 ± 0.4 8.8 ± 0.4 0.10
K2 21.1 ± 2.8 17.2 ± 0.9 18.1 ± 0.3 0.11
KA × 109 (M−1) 6.2 ± 0.8a 3.3 ± 0.4b 2.9 ± 0.2b < 0.001
KD × 1010 (M) 1.8 ± 0.3a 3.4 ± 0.5b 3.7 ± 0.3b < 0.001
VLDL2-rich
ka1 × 105 (M−1s−1) 11.9 ± 1.6 10.3 ± 1.7 10.2 ± 1.0 0.28
kd1 × 10−3 (s−1) 7.8 ± 1.4 6.4 ± 1.4 6.7 ± 0.8 0.25
K1 × 108 (M−1) 1.8 ± 0.3 1.6 ± 0.4 1.8 ± 0.3 0.59
ka2 × 10−2 (s−1) 1.7 ± 0.2a 1.3 ± 0.3a,b 1.3 ± 0.2b 0.011
kd2 × 10−4 (s−1) 8.9 ± 0.6 9.3 ± 0.4 10.5 ± 1.0 0.46
K2 20.7 ± 3.7 42.1 ± 24.8 13.3 ± 2.1 0.41
KA × 109 (M−1) 3.8 ± 0.6 3.0 ± 0.5 2.4 ± 0.4 0.09
KD × 1010 (M) 3.7 ± 0.8 4.6 ± 1.0 5.9 ± 1.5 0.265
Table 2.  Effect of meal fat composition on the binding properties of postprandial VLDL1-rich and VLDL2-
rich particles to the LDLR. Values represent mean ± SEM for n = 10 independent SPR samples for the VLDL1 
and VLDL2-rich fractions, respectively. Abbreviations: SFA, saturated fatty acid meal; SFA-FO, SFA meal with 
fish oil; UNSAT, unsaturated fatty acid meal. Data for the two genotype groups combined were analyzed using a 
one-way repeated measures ANOVA followed by Student’s t test with Bonferroni correction (P < 0.017). Values 
within each row with different superscript letters are significantly different.
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with reduced LDLR (a core receptor which facilitates the hepatic removal of LDL and TRL from the circulation) 
expression36. Here the focus is on the interaction of lipoproteins with the LDLR. Overall, using the newly devel-
oped SPR approach, our fasting data indicates lower LDL and increased VLDL1- rich particle binding to the 
LDLR in APOE4 carriers. In the postprandial state, consumption of the SFA meal resulted in enhanced binding 
of VLDL1-rich (overall K1 and overall KA) and VLDL2- rich particles (ka2) and associated strong trends towards 
reduced HepG2 125I-labelled LDL uptake in APOE4 carriers when these particles were co-incubated. Collectively 
these effects on LDLR interactions and hepatic LDL uptake provide an explanation for the higher circulating 
LDL-cholesterol concentrations in APOE4 carriers, in particular in response to increased dietary SFA intakes.
Our analysis revealed APOE genotype to influence both stages of the LDL-LDLR binding process, with a 1.5 
fold slower initial rate of association of APOE3/E4 LDL fraction particles with the LDLR (ka1). In addition, the 
rate of dissociation (kd1) was also higher suggesting a lower stability of the LDL-LDLR complex in APOE3/
E4 samples, which would be predicted to result in a slower liver LDL receptor-mediated endocytosis. A slower 
association rate was also observed with the fasting VLDL1-rich particles from the APOE3/E4 group, but once 
the VLDL1-LDLR complex was formed, it was found to be more stable and dissociated at a slower rate than the 
APOE3/E3 VLDL-1 rich fraction. This finding explains the lower percentage binding of 125I-labelled LDL to the 
HepG2 cell surface (the heparin releasable fraction comprises particles bound to the LDLR, heparin-sulphate 
proteoglycans (HSPG) and other receptors) in the presence of the APOE3/E4 VLDL1-rich fraction. Although a 
similar relationship was also observed in the HepG2 cell studies with the VLDL2-rich fraction, genotype was not 
shown to influence the SPR binding kinetics of this TRL fraction to the LDLR. Differences between the findings 
of the SPR and HepG2 cell experiments with respect to the VLDL2-rich fraction may reflect greater involvement 
of proteins on the cell surface (such as HSPG) for mediating the binding of this TRL fraction to the LDLR. Our 
SPR technique may provide some insights into this as we observed the binding characteristics of the VLDL2-rich 
fraction to be intermediate between the VLDL1-rich fraction and LDL, which are thought to utilize apoE and 
apoB-100, respectively, as a ligand for receptor-mediated uptake. Although it has been proposed that VLDL2 uses 
apoB-100 as a ligand13, our data suggest that apoE may also facilitate binding of these TRL fraction particles to 
the LDLR.
Our findings from the 125I-labelled LDL uptake studies in the presence of fasting TRL are in agreement with 
a previous in vitro study which reported a greater binding affinity of VLDL isolated from APOE4 homozygotes 
Fasting Postprandial P for ANOVA
APOE3/E3 APOE3/E4 P
APOE3/E3 APOE3/E4
Meal Genotype Meal × genotypeSFA SFA-FO UNSAT SFA SFA-FO UNSAT
VLDL1-rich
Heparin1 108.2 ± 3.5 49.8 ± 12.1 0.001 63.7 ± 10.0 65.5 ± 9.2 66.1 ± 11.4 51.2 ± 7.3a 82.6 ± 13.4b 84.8 ± 18.5b 0.023 0.63 0.046
Cell associated1 54.9 ± 7.4 59.3 ± 5.9 0.67 77.6 ± 7.8 84.2 ± 8.1 71.8 ± 6.3 66.0 ± 17.8 81.7 ± 17.6 70.4 ± 8.7 0.036 0.74 0.48
Deg. Products1 88.2 ± 8.2 81.2 ± 3.9 0.51 59.9 ± 13.4 66.8 ± 13.3 73.8 ± 15.9 77.8 ± 21.8 89.6 ± 19.3 94.0 ± 20.1 0.17 0.49 0.43
Total uptake1 65.3 ± 5.6 68.5 ± 2.4 0.89 70.1 ± 8.7 76 ± 8.8 69.1 ± 9.8 67.6 ± 8.8a 81.9 ± 8.4b 79.9 ± 9.8b 0.053 0.89 0.07
VLDL2-rich
Heparin 109.2 ± 9.9 75.1 ± 8.3 0.038 61.8 ± 12.8 58.1 ± 10.6 55.0 ± 11.0 62.1 ± 10.3 91.1 ± 34.7 86.9 ± 21.0 0.39 0.37 0.16
Cell assoc 77.0 ± 6.8 88.6 ± 5.9 0.25 54.8 ± 11.7 57.0 ± 13.7 49.9 ± 9.0 56.9 ± 13.8a 89.0 ± 21.9b 70.5 ± 16.9a 0.019 0.38 0.047
Deg products 92.3 ± 7.7 70.9 ± 7.5 0.32 54.4 ± 8.9 44.8 ± 6.3 50.4 ± 6.8 60.5 ± 16.9 94.6 ± 44.7 82.1 ± 29.3 0.12 0.33 0.07
Total uptake 81.9 ± 6.7 81.8 ± 6.3 0.32 54.9 ± 9.5 51.9 ± 10.5 50.6 ± 8.0 55.7 ± 8.2 88.1 ± 26 73 ± 18.2 0.13 0.32 0.07
Table 3.  Summary measures for the uptake of 125I-labelled LDL by HepG2 cells in the presence of ex vivo 
VLDL1 and VLDL2-rich TRL fractions isolated from fasting and postprandial plasma samples. Data are 
mean ± SEM for the percentage change in heparin releasable binding, cell associated radioactivity, degradation 
products and total uptake of 125I-labelled LDL after 5 h in the presence of VLDL1 and VLDL2-rich fractions, 
compared with 125I-labelled LDL in the absence of TRL. Each experiment was performed in duplicate and 
represents n = 5 independent experiments for APOE3/E3 and n = 4 independent experiments for APOE3/E4 
group. Heparin- refers to the heparin releasable, cell surface bound 125I-LDL, Cell associated- refers to the 125I-
LDL which has been internalized into the cell, Deg. products- refers to the degradation products which have 
been released by the cell back into the medium, Total uptake is the sum of the cell surface bound (heparin), cell 
associated and degradation products. The absolute values for the total uptake of 125I-labelled LDL in the absence 
of TRL was 948 ± 137 ng/mg cell protein (heparin releasable binding 40 ± 5 ng/mg cell protein, cell associated 
radioactivity 587 ± 81 ng/cell protein and degradation products 323 ± 37 ng/cell protein) and 881 ± 127 ng/
cell protein (heparin releasable binding 38 ± 5 ng/cell protein, cell associated radioactivity 480 ± 76 ng/cell 
protein and degradation products 363 ± 53 ng/cell protein) for APOE3/E3 and APOE3/E4 LDL, respectively. 
In the fasting state, differences between genotype groups were compared using the Student’s independent t-test 
(P ≤ 0.05). For the TRLs isolated after the saturated fatty acid meal (SFA), SFA meal with fish oil (SFA-FO) 
and unsaturated fatty acid meal (UNSAT), data were analyzed using a mixed factor ANOVA. When the 
meal*genotype interaction were significant, one way repeated measures ANOVA followed by Student’s t test 
with Bonferroni correction (P < 0.017) were used to determine differences between meals within each genotype 
group. Values with different superscript letters within each row are significantly different.
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in the fasted state to the LDLR37 but also indicate that this phenomenon is evident in APOE4 heterozygotes. 
However, the total uptake of 125I-labelled LDL was not different between the genotype groups suggesting that 
raised fasting LDL-cholesterol concentrations in APOE3/E4 individuals may be associated with, (i) delayed clear-
ance of LDL from the circulation (as a result of the greater competition with TRL for binding to the LDLR), or 
(ii) preferential uptake of TRL by the liver which augments the hepatic cholesterol pools, reducing LDLR expres-
sion. Interestingly, in the present study, the fasting VLDL1-rich fraction was shown to reduce 125I-labelled LDL 
uptake to a greater extent than the VLDL2-rich fraction. This is in contrast to our previous observation, which 
showed the fasting VLDL2-rich fraction isolated from E4 carriers following DHA supplementation to compete 
to a greater extent with 125I-labelled LDL for uptake, compared with VLDL1-rich fraction (6). These differences 
may reflect the acute nature of our current study design or the use of LDL isolated from the same APOE genotype 
group in our HepG2 competition experiments.
Although the amino acids present at positions 112 and 158 of the apoE protein are not within the receptor 
binding region (amino acids 136–150), it has been demonstrated that amino acid changes at these sites impact 
on the salt bridge formation and the 3D protein conformation which is likely to affect receptor binding activity38. 
It has also been proposed that the variable receptor binding of lipoprotein-associated apoE could be as a conse-
quence of the two different lipid-bound states of the apoE molecule39. The LDLR binding domain in apoE is only 
recognized when the helix bundle is open, so only molecules in this conformation will act as effective ligands 
for this receptor40. This conformational change may support the two-step model seen in our sensorgrams when 
apoE binds to LDLR, as similar results have been reported by Nguyen et al., when determining the binding of 
apoE to VLDL particles18. According to this, the second step of the reaction (formation of AB*), corresponds at 
least in part to the rate at which the helix bundle opens. The shift from AB to AB* regulated by ka2 (when the 
apoE-VLDL interaction was studied by SPR) has been reported to occur faster in APOE4 carriers than in APOE3/
E318. However, in our study, a similar ka2 constant was observed for both fasting LDL and TRL isolated from the 
APOE3/E3 and APOE3/E4 groups, suggesting that the higher binding affinity in APOE4 carriers may reflect the 
conformation of APOE4 on the surface of these particles which, due to the lower stability of the helix bundle, 
binds to the receptor in the open conformation.
In the present study, APOE genotype was shown to have a significant impact on the binding properties of 
fasting LDL and TRL particles for the LDLR whereas meal fat composition influenced the binding kinetics of 
the postprandial TRL particles. Irrespective of the APOE genotype, a greater binding affinity for the LDLR was 
observed with particles isolated after the SFA-rich than UNSAT or SFA-FO meals, although this was only signif-
icant for the VLDL1-rich fraction. This finding is in agreement with an earlier in vitro study, in which the uptake 
of 125I-labelled LDL was reduced by the presence of apoE-rich Sf 60–400 particles isolated after a SFA-rich meal14. 
In the postprandial state, the metabolism of TRL particles has been shown to be altered by enrichment with 
‘exchangeable’ apolipoproteins such as apoE41. Consistent with our previous study, the apoE: apoB ratio was also 
higher in the postprandial VLDL1-rich fraction after the SFA meal indicating that the test meal fat composition 
impacts on both the number and orientation of the apoE molecules on the particle surface41. Since apoE can exist 
in two different states when bound to lipids40,42,43, we speculate that apoE presents in an open helix structure on 
the post-meal TRL particles leading to an unmasking of the binding domain for the LDLR after the SFA relative 
to either SFA-FO or UNSAT meals.
Our findings suggest that the LDLR may play a more important role in the uptake of VLDL1-rich particles 
after a meal containing predominately SFA than UNSAT, which may reflect the effects of SFA on TRL particle 
composition. Individual LDL particles are reported to bind with single LDLR44, which are clustered together 
in coated pits on the surface of liver cells. The binding of large TRL enriched in apoE to one or multiple LDLR, 
may physically prevent the binding of LDL to the LDLR, thus reducing the number of LDL particles bound and 
therefore internalized and degraded by the liver45. The observation of a lower percentage binding of 125I-labelled 
LDL to the HepG2 cell surface in the presence of VLDL1-rich particles isolated after the SFA meal suggests that 
this may be a physiological phenomenon. However, the HepG2 cell studies are based on the uptake of radiola-
beled LDL which can only determine the fate of the LDL particles, with no information about the uptake of the 
unlabeled TRL by the liver cells. This could occur via the LDLR, or they could influence LDL uptake by binding to 
other receptors on the cells such as the LDLR related protein, influencing cellular cholesterol concentrations and 
expression of the LDLR on the liver cell surface. Further work is required to determine the effects of meal fatty 
acid composition on the orientation of apoE on the particle surface and kinetics of binding of TRL isolated from 
different APOE genotype groups to the HSPG, LDLR and related receptors.
The development of our SPR technique has provided novel insights into the interaction of intact lipoproteins 
with the LDLR, with our complementary HepG2 cell studies providing a more physiological representation of 
the receptor-mediated uptake of LDL by liver cells in the presence of circulating TRL particles. These findings 
provide a mechanistic basis for the higher LDL-cholesterol associated with SFA-rich diets, and in particular in 
APOE4 carriers.
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